Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

BACKGROUND: The effectiveness of MAPK pathway inhibitors (MAPKi) used to treat patients with BRAF-mutant melanoma is limited by a range of resistance mechanisms, including soluble TNF (solTNF)-mediated NF-kB signaling. solTNF preferentially signals through type-1 TNF receptor (TNFR1), however, it ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Cindy A., Rush, Elizabeth A., Shi, Jian, Arantes, Lidia M. R. B., Tesi, Raymond J., Ross, Mark A., Calderon, Michael J., Watkins, Simon C., Kirkwood, John M., Ferris, Robert L., Butterfield, Lisa H., Vujanovic, Lazar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310383/
https://www.ncbi.nlm.nih.gov/pubmed/35879777
http://dx.doi.org/10.1186/s12967-022-03538-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310383/
https://www.ncbi.nlm.nih.gov/pubmed/35879777
http://dx.doi.org/10.1186/s12967-022-03538-w

Ejemplares similares